“Lenacapavir is a product with real transformational potential that has the power to change the history of HIV,” Carolyn Amole of the Clinton Health Access Initiative (CHAI) told the 13th International AIDS Society Conference on HIV Science (IAS 2025) in Kigali, Rwanda. But for that potential to be achieved, it must be delivered at scale, and for that it needs to brought rapidly to market at an affordable price, she said.
This extraordinarily efficacious form of PrEP – only requiring injections every six months – arrives at a precarious time. The Trump administration’s radical cuts to the global health programme PEPFAR remove the institution which funded over 90% of PrEP users worldwide and which was expected to make major investments in lenacapavir.
Read the full news story at aidsmap.
All aidsmap reports from IAS 2025 can be accessed here.
Source : aidsmap
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.